Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency
- PMID: 29996551
- PMCID: PMC6070928
- DOI: 10.3390/cancers10070231
Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency
Abstract
Oncolytic virus (OV) therapy has emerged as a promising approach for cancer treatment with the potential to be less toxic and more efficient than classic cancer therapies. Various types of OVs in clinical development, including Vaccinia virus (VACV)-derived OVs, have shown good safety profiles, but limited therapeutic efficacy as monotherapy in some cancer models. Many different methods have been employed to improve the oncolytic potency of OVs. In this study, we used a directed evolution process, pooling different strains of VACV, including Copenhagen, Western Reserve and Wyeth strains and the attenuated modified vaccinia virus Ankara (MVA), to generate a new recombinant poxvirus with increased oncolytic properties. Through selective pressure, a chimeric VACV, deVV5, with increased cancer cell killing capacity and tumor selectivity in vitro was derived. The chimeric viral genome contains sequences of all parental strains. To further improve the tumor selectivity and anti-tumor activity of deVV5, we generated a thymidine kinase (TK)-deleted chimeric virus armed with the suicide gene FCU1. This TK-deleted virus, deVV5-fcu1 replicated efficiently in human tumor cells, and was notably attenuated in normal primary cells. These studies demonstrate the potential of directed evolution as an efficient way to generate recombinant poxviruses with increased oncolytic potency, and with high therapeutic index to improve cancer therapy.
Keywords: deVV5-fcu1; directed evolution; genome shuffling; vaccinia virus.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6070928/bin/cancers-10-00231-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6070928/bin/cancers-10-00231-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6070928/bin/cancers-10-00231-g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6070928/bin/cancers-10-00231-g004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6070928/bin/cancers-10-00231-g005.gif)
Similar articles
-
Oncolytic properties of non-vaccinia poxviruses.Oncotarget. 2018 Nov 13;9(89):35891-35906. doi: 10.18632/oncotarget.26288. eCollection 2018 Nov 13. Oncotarget. 2018. PMID: 30542506 Free PMC article.
-
Cowpox Virus: A New and Armed Oncolytic Poxvirus.Mol Ther Oncolytics. 2017 Aug 24;7:1-11. doi: 10.1016/j.omto.2017.08.003. eCollection 2017 Dec 15. Mol Ther Oncolytics. 2017. PMID: 28951885 Free PMC article.
-
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism.Mol Ther Oncolytics. 2019 Mar 27;14:1-14. doi: 10.1016/j.omto.2019.03.005. eCollection 2019 Sep 27. Mol Ther Oncolytics. 2019. PMID: 31011628 Free PMC article.
-
Design Strategies and Precautions for Using Vaccinia Virus in Tumor Virotherapy.Vaccines (Basel). 2022 Sep 17;10(9):1552. doi: 10.3390/vaccines10091552. Vaccines (Basel). 2022. PMID: 36146629 Free PMC article. Review.
-
Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.Curr Pharm Biotechnol. 2012 Jul;13(9):1768-72. doi: 10.2174/138920112800958922. Curr Pharm Biotechnol. 2012. PMID: 21740365 Review.
Cited by
-
Tumor Tropism of DNA Viruses for Oncolytic Virotherapy.Viruses. 2023 Nov 16;15(11):2262. doi: 10.3390/v15112262. Viruses. 2023. PMID: 38005938 Free PMC article. Review.
-
Oncolytic virus therapy in cancer: A current review.World J Virol. 2021 Sep 25;10(5):229-255. doi: 10.5501/wjv.v10.i5.229. World J Virol. 2021. PMID: 34631474 Free PMC article. Review.
-
Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements.Cancers (Basel). 2021 Feb 3;13(4):588. doi: 10.3390/cancers13040588. Cancers (Basel). 2021. PMID: 33546172 Free PMC article. Review.
-
Viroimmunotherapy for breast cancer: promises, problems and future directions.Cancer Gene Ther. 2021 Aug;28(7-8):757-768. doi: 10.1038/s41417-020-00265-6. Epub 2020 Dec 2. Cancer Gene Ther. 2021. PMID: 33268826 Free PMC article. Review.
-
Novel Chimeric Poxvirus CF17 Improves Survival in a Murine Model of Intraperitoneal Ovarian Cancer Metastasis.Mol Ther Oncolytics. 2020 Oct 10;19:278-282. doi: 10.1016/j.omto.2020.10.002. eCollection 2020 Dec 16. Mol Ther Oncolytics. 2020. PMID: 33251335 Free PMC article.
References
-
- Heinrich B., Klein J., Delic M., Goepfert K., Engel V., Geberzahn L., Lusky M., Erbs P., Preville X., Moehler M. Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: Studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes. OncoTargets Ther. 2017;10:2389–2401. doi: 10.2147/OTT.S126320. - DOI - PMC - PubMed
-
- Fend L., Yamazaki T., Remy C., Fahrner C., Gantzer M., Nourtier V., Préville X., Quemeneur E., Kepp O., Adam J., et al. Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy. Cancer Res. 2017;77:4146–4157. doi: 10.1158/0008-5472.CAN-16-2165. - DOI - PubMed
-
- Andtbacka R.H., Kaufman H.L., Collichio F., Amatruda T., Senzer N., Chesney J., Delman K.A., Spitler L.E., Puzanov I., Agarwala S.S., et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J. Clin. Oncol. 2015;33:2780–2788. doi: 10.1200/JCO.2014.58.3377. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources